INTRODUCTION
============

*Helicobacter pylori* infection is associated with development of gastroduodenal diseases such as duodenal and gastric ulcers, mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma.[@b1-gnl-13-531],[@b2-gnl-13-531] To reduce the risk of these diseases, there has been continued interest in the elimination of *H. pylori*.[@b3-gnl-13-531] The clarithromycin-containing triple therapy (TT), including amoxicillin and clarithromycin combined with a conventional proton-pump inhibitor (PPI), has long been recommended as the first-line treatment for *H. pylori* eradication and is the most commonly used treatment. It is also suggested by many international and Korean guidelines.[@b4-gnl-13-531]--[@b6-gnl-13-531] However, the major problem of TT is its clinical efficacy, which has significantly decreased globally to the point of unacceptable levels in many countries.[@b7-gnl-13-531]--[@b9-gnl-13-531] This is mostly caused by increased antimicrobial resistance, including clarithromycin resistance.[@b10-gnl-13-531] Similarly, the eradication rate in Korea has been steadily decreasing over the past 20 years and has recently been reported to be 70% to 75%.[@b11-gnl-13-531]--[@b14-gnl-13-531] However, the Kyoto Global Consensus Report suggests that only regimens with an eradication rate of 90% or more in the area should be used as the sole empirical treatment, making it imperative to find a regimen that provides a more favorable eradication rate.[@b15-gnl-13-531] Recently, although susceptibility-based merits were suggested, the cost-effectiveness of this strategy has not been rigorously evaluated.[@b16-gnl-13-531] Because no evidence supports the superiority of tailored therapy over empirical therapy at the nation level, optimal empirical regimen still needs to be determined.

Several alternative therapies have been proposed, including bismuth-containing quadruple therapy and non-bismuth-containing quadruple therapy.[@b17-gnl-13-531] A non-bismuth-containing quadruple therapy known as concomitant therapy (CT) may be an alternative and has been found to be effective in an environment of high clarithromycin resistance.[@b18-gnl-13-531] Furthermore, some randomized trials have suggested that CT in the Korean population is likely to be more effective than the sequential therapy (ST).[@b19-gnl-13-531],[@b20-gnl-13-531] ST is among the proposed therapies and is relatively less dependent on clarithromycin sensitivity and therefore expected to be a suitable first-line regimen. Furthermore, a meta-analysis reported that ST was comparably more effective than TT, although a variation in efficacy was found because of regional differences in antibiotic resistance.[@b21-gnl-13-531]--[@b23-gnl-13-531] Despite previous results, there were issues of inadequate quality of research design, insufficient sample size, and most studies were single institutional or local studies in Korea. Thus, it is highly important to conduct a well-designed nationwide population-based trial to determine the most appropriate first-line treatment regimen for Korean subjects. Such a trial enables providing a basis for changing the primary treatment in light of the domestic reality, as well as providing specific alternatives in Korea. In fact, the study was endorsed by the Korean government as part of an effort to prevent gastric cancer by eradicating *H. pylori* in Korea.

Therefore, the primary endpoint was to demonstrate the difference in eradication rates between CT for 10 days versus TT, ST for 10 days versus TT, respectively. Our secondary aim was to evaluate drug compliance and adverse events of the three treatment groups.

MATERIALS AND METHODS
=====================

1. Study design
---------------

This was a multicenter, prospective, randomized, three-armed, superiority, parallel-group, open label trial which was performed at fifteen institutions nationwide in Korea. The study design has been published previously,[@b24-gnl-13-531] and the protocol was approved by the Institutional Review Board of the Samsung Medical Center, Korea (IRB number: SMC 2016-02-131-002), and all participating centers also approved committee approval. The study was conducted in accordance with the standards of the Declaration of Helsinki and the Food and Drug Administration regulations regarding Good Clinical Practice. Written informed consent was obtained from all participants. This investigator-initiated trial is registered at <https://cris.nih.go.kr/cris> (Identifier number: KCT0001980). [Fig. 1](#f1-gnl-13-531){ref-type="fig"} demonstrates a flow diagram of this trial.

2. Patients
-----------

This trial included *H. pylori*-infected patients aged ≥19 years who agreed to trial participation, provided written informed consent, and fulfilled the eligibility criteria. In addition, those who met the following criteria were excluded: patients with a previous history of *H. pylori* infection management; patients with a gastric surgical history; patients with a history of antibiotic therapy within the prior 1 month; patients with a history of PPI use within the prior 2 weeks; patients with a history of taking various drugs; patients with serious concomitant illnesses; pregnant participants.[@b24-gnl-13-531] Antibiotics or other medications affecting the treatment results were prohibited during the study period.

3. Randomization and allocation concealment
-------------------------------------------

A centralized web-based randomization system, which uses permuted block randomization with a concealed and varying block size, was used for randomization. To ensure concealed allocation, an independent staff dispensed consecutively numbered, identically designed treatment packs that contained sealed bottles of study drugs. Participants were not blinded to group allocation.

4. Procedures
-------------

In the treatment group, the experimental arm 1 group received the 10d-ST (lansoprazole 30 mg and amoxicillin 1 g twice daily for the first 5 days followed by lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg twice daily for the remaining 5 days), and the experimental arm 2 group received CT (10d-CT; lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 10 days). In addition, the control group received the triple regimen (7d-TT; lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 7 days). Before enrollment, rapid urease test, urea breath test (UBT), and/or histology was performed for the evaluation of *H. pylori* infection status. Adverse event and compliance were evaluated at the first visit after allocation. At the second visit, the efficacy of *H. pylori* eradication therapy was determined. UBT was conducted to assess *H. pylori* status at the 4th to 6th week after the end of *H. pylori* eradication therapy. A staff member blinded to the eradication arm of each patient performed the UBT.

5. Outcomes
-----------

The primary endpoint of the study is the *H. pylori* eradication rate. The secondary endpoints are the adverse events and treatment compliance. Adverse events were evaluated using the Common Terminology Criteria for Adverse Events v4.0.[@b25-gnl-13-531] Adherence to treatment was assessed by providing all patients with a prestructured printed table with all dosages illustrated. Poor compliance was defined as the use of less than 80% of the total medication prescribed.[@b11-gnl-13-531],[@b26-gnl-13-531]

6. Statistical considerations
-----------------------------

The eradication rate of 7d-TT is approximately 75% in Korea,[@b27-gnl-13-531] and the eradication rate of sequential or CT has been reported to be more than 80%.[@b28-gnl-13-531],[@b29-gnl-13-531] To obtain the optimal eradiation rate, an eradication efficacy of more than 85% is needed. Therefore, we hypothesized that the eradication rate would be superior in the 10d-ST or 10d-CT groups, with a 10% difference compared to the rate for 7d-TT (85% vs 75%). To demonstrate this 10% difference in the eradication rate using a statistical power of 80% and type one error rate of 0.025 allowing maximum 20% of the participant drop-out or noncompliance, the protocol requires 1,137 subjects.

All efficacy analyses were evaluated for the intent-to-treat (ITT) and per-protocol (PP) populations. The primary endpoint was assessed in the ITT population. All randomized subjects were included in the ITT analysis. Patients who did not return for a follow-up UBT were considered treatment failures. In the PP analysis, patients with unknown *H. pylori* status following therapy and those with major protocol violations were excluded. Subjects who received at least one dose of eradication drugs were included in the safety analysis. SAS 9.4 (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis. All statistical tests were two-sided, and p-value 0.025 was used as cutoff for the statistical significance of the primary outcome analysis, while p-value 0.05 was adopted for all other statistical tests.

RESULTS
=======

1. Clinical characteristics of the study groups
-----------------------------------------------

A total of 1,141 patients from 15 hospitals from October 2016 to October 2018 were screened for eligibility. Of these, 1,137 patients were included and randomly assigned to receive a 7d-TT group (n=377), 10d-CT group (n=383), or 10d-ST group (n=377) ([Fig. 1](#f1-gnl-13-531){ref-type="fig"}). The baseline characteristics of patients in each study group are summarized in [Table 1](#t1-gnl-13-531){ref-type="table"}. There was no significant difference in age, sex, residence, smoking, alcohol consumption, past medical history, and family history of gastric cancer between the three groups. There was no significant difference in the indication of *H. pylori* eradication between treatment groups. Gastric or duodenal ulcers and post-endoscopic resection for gastric cancer and MALT lymphoma were, respectively, included in 28.0%, 8.4%, and 0.5% of the TT group; in 25.8%, 6.7%, and 0.2% of the CT group; and in 29,1%, 5.5%, and 0.3% of the ST group.

2. Eradication efficacy of *H. pylori*
--------------------------------------

The primary goal was eradication rates of treatments by ITT and PP analysis. The 10d-CT and 10d-ST had a higher eradication rate than the 7d-TT. The 10d-CT achieved a markedly higher eradication rate than the 7d-TT. The eradication rates in the ITT analyses for the 7d-TT and 10d-CT groups were 63.9% and 81.2%, respectively (p\<0.001) ([Fig. 2](#f2-gnl-13-531){ref-type="fig"}). The eradication rates in the PP analyses for the 7d-TT and 10d-CT groups were 71.4% and 90.6%, respectively (p\<0.001) ([Fig. 3](#f3-gnl-13-531){ref-type="fig"}). The eradication rate of the 10d-ST was superior to that of 7d-TT. The eradication rates in the ITT analyses for the 7d-TT and 10d-ST groups were 63.9% and 76.3%, respectively (p\<0.001). The eradication rates in the PP analyses for the 7d-TT and 10d-ST groups were 71.4% and 85.0%, respectively (p\<0.001).

3. Factors affecting *H. pylori* eradication
--------------------------------------------

First, we identified age group, sex, treatment regimen, and compliance which were significant in the univariate analysis and verified whether those covariates are all statistically significant in the multiple logistic regression model. Especially, 10d-CT group has higher related with *H. pylori* eradication than the 7-d TT with statistical significance (odds ratio \[OR\], 3.40; 95% confidence interval \[CI\], 2.34 to 4.94) ([Table 2](#t2-gnl-13-531){ref-type="table"}). Second, clinical factors such as treatment regimen, age, sex, and compliance were identified as risk factors associated with successfully eradicated and failed patients between 7d-TT and 10d-ST groups in the univariate logistic model. In multiple logistic model, 10d-ST has higher association with eradication rate than 7d-TT (OR, 2.10; 95% CI, 1.50 to 2.95) ([Table 3](#t3-gnl-13-531){ref-type="table"}).

4. Treatment compliance and adverse events
------------------------------------------

The secondary outcomes were treatment compliance and adverse events. The compliance with *H. pylori* eradication therapy of the 7d-TT, 10d-CT, and 10d-ST groups were 91.21, 86.0, and 88.0, respectively (p=0.004). At least one adverse event was recorded in 33.2% (n=378) of the 1,137 patients, and in total, 602 adverse events were recorded. The incidences of adverse events were 29.7% in 7d-TT, 36.5% in 10d-CT, and 33.4% in 10d-ST groups, respectively ([Table 4](#t4-gnl-13-531){ref-type="table"}). Diarrhea was the most common adverse event in all three treatment groups. Diarrhea (n=42), dysgeusia (n=36), and dyspepsia (n=12) were the most common adverse reactions in the 7d-TT group. Diarrhea (n=51), dysgeusia (n=34), and non-cardiac chest pain (n=23) were the most common adverse reactions in the 10d-CT group. Diarrhea (n=28), nausea (n=26), and dysgeusia (n=21) were the most common events in the 10d-ST group. However, there were no serious adverse events associated with the present study. There was little difference in serious side effects among the three treatment groups.

DISCUSSION
==========

This multicenter randomized controlled trial of three regimens for *H. pylori* eradication involved a large sample of patients recruited from the general populations in Korea. In particular, this is a nationwide, most systematic, and verifiable study that best represents Korea. In this clinical setting, we have demonstrated a higher eradication rate in both the 10d-CT and 10d-ST novel approaches.

Data demonstrate that 10d-CT achieves significantly higher eradication rates than 7d-TT, regardless of whether ITT or PP analysis is used. The eradication rate of 10d-CT and 10d-ST was higher than that of 7d-TT. There was little difference in serious adverse events among the three treatment groups.

*H. pylori* eradication is of great importance in preventing gastric cancer. In Japan, eradication treatment is allowed in all cases where *H. pylori* infection has been confirmed, since 2013. In Korea, the indication for *H. pylori* eradication is expanding, but the increase in the failure rate of the first-line eradication requires the development of a new first-line standard treatment. Therefore, to the best of our knowledge, this is the first large-scale prospective study to present the optimal standard first-line treatment for *H. pylori*, which is suitable for domestic conditions in Korea.

Globally, the primary option for *H. pylori* eradication is clarithromycin-based TT, which includes a PPI and two antibiotics, amoxicillin and clarithromycin.[@b9-gnl-13-531] Because the incidence of resistance to clarithromycin in *H. pylori* has been increasing, the eradication rates of TT have decreased to less than 80%, which is considered below the appropriate therapeutic range.[@b30-gnl-13-531],[@b31-gnl-13-531] To overcome the low eradication rate of clarithromycin therapy, many researchers have developed other therapeutic options such as prolonged treatment schedules or modified drug administration sequences including CT and ST.[@b32-gnl-13-531]

In Korea, no alternative treatment has been established so far to replace the 7d-TT. Instead, 7d- or 14d-clarithromycin-based TT is still recognized as the first-line therapy in the Korean national guidelines.[@b5-gnl-13-531] Furthermore, Health Insurance Review and Assessment Service of the Korean government approves only 7d-TT as the first-line *H. pylori* therapy.[@b33-gnl-13-531] Our previous study showed the regional difference in eradication rate as first-line treatment in Korea.[@b11-gnl-13-531] One Korean study reported different rates of resistance to clarithromycin prepared using the agar dilution method, suggesting that different guidelines should be applied to eradicate *H. pylori* based on antibiotic resistance even within the same country or ethnic group.[@b34-gnl-13-531]

Recent studies have carried out randomized trials including bismuth-containing quadruple therapy, widely used as a second-line eradication therapy.[@b23-gnl-13-531],[@b35-gnl-13-531] In this trial, we compared all three currently used therapeutic regimens: 7d-TT, 10d-CT, and 10d-ST. In practical terms, comparisons among the three groups would result in more accurate results, but they would have to include more patients and take longer to implement.

CT includes the use of both PPI and three antibiotics at the same time, although it may lead to antibiotic abuse and unnecessary resistance. There was no difference in the clinical efficacy of CT in clarithromycin-sensitive and clarithromycin-resistant groups[@b36-gnl-13-531] as well as in metronidazole-sensitive and metronidazole-resistant groups.[@b37-gnl-13-531] In clinical practice, the concomitant regimen is much easier to take than the sequential one, which is a two-stage therapy with a drug switch halfway through the course. A meta-analysis revealed that CT was superior to TT, and there was no difference in the eradication rates of CT and ST (93.0% vs 93.1%, respectively).[@b38-gnl-13-531] Unfortunately, there is little research data on CT in Korea.

ST was effective in case of clarithromycin resistance,[@b39-gnl-13-531] metronidazole resistance,[@b40-gnl-13-531] and even resistance to both clarithromycin and metronidazole.[@b39-gnl-13-531] ST was reported to be more effective than 7d-TT in many Asian countries.[@b35-gnl-13-531] However, the shortcoming of ST is that medications were changed during treatment and patients found it difficult to take them.[@b32-gnl-13-531] A recent systematic review from six Korean randomized trials revealed that the overall eradication rates by ITT analysis were 65.9% for 7d-TT and 77.7% for ST.[@b41-gnl-13-531] The overall eradication rates were 72.6% for 7d-TT and 84.5% for ST by PP analysis.

Overall, in this study, 10d-CT and 10d-ST showed superior clinical efficacy to 7d-TT as first-line therapy for *H. pylori* infection. Our data support those of previous study, as they demonstrate that the 10d-CT achieved a significantly higher eradication rate than the 10d-TT.[@b42-gnl-13-531] From the ITT analysis, the eradication rate of the 10d-CT was 81.2% in our study, which was 17.3% better than that of the 7d-TT (p\<0.001). In addition, comparison results of the 10d-ST and 7d-TT groups indicated that 10d-ST was 12.4% more effective than the 7d-TT (p\<0.001). Until recently, results of the 10d-ST in Korea were found to be above the 7d-standard clarithromycin-containing TT.[@b43-gnl-13-531] However, the 10d-ST demonstrated lower eradication rates than expected so far.[@b44-gnl-13-531]--[@b46-gnl-13-531]

Several studies have shown no difference in the effectiveness of CT and ST in clarithromycin and metronidazole-sensitive or clarithromycin and metronidazole-resistant groups.[@b26-gnl-13-531],[@b38-gnl-13-531] In this study, the eradication rate of CT appeared to be better than that of ST, although direct comparison was not possible.

Drug compliance is one of the important elements in determining the treatment outcome in bacterial eradication, especially for short-term treatment.[@b26-gnl-13-531] In this study, three therapies were well tolerated and showed similar adverse event profiles and frequencies. In fact, 34.0% of the patients observed adverse events, which were minor or moderate.

Many studies have evaluated the factors affecting *H. pylori* eradication rates, such as antibiotic resistance, and various types of gastropathy, alcohol consumption, smoking, hyperlipidemia, and comorbidity.[@b32-gnl-13-531] This study surveyed the results of both the successful and failed eradication according to each regimen comparison.

As regards age, sex, treatment regimen, compliance, general medical history except gastrointestinal system, medical history of gastrointestinal diseases, family history of gastric cancer, concomitant medication, the notable factors were treatment regimen, sex, and compliance. Interestingly, in this study, although men are more prone to eradication failure than women, the rate of eradication for women was lower than for men. Although metronidazole is widely used to treat gynecologic diseases and resistance to metronidazole frequently occurs in Korea, the reasons for the contradictory results were unclear.

The strength of this study is that it is the first nationwide large-scale randomized controlled trial assessing the efficacies of 10d-CT and 10d-ST versus a 7d-TT for treating *H. pylori* infection. Especially, this study represented the Korean population because it took into account regional distribution. Moreover, this study was conducted in Korea where the prevalence of *H. pylori* and gastric cancer is high. The fact that the research was conducted on a large scale through a nationwide network based on the Korean population with *H. pylori* infection and upper gastrointestinal research with the support of the Korean government is worth noting. Furthermore, a separate statistical and research management institution, Seoul National University Hospital Medical Research Collaboratory Center, was involved in providing professional analyses in this study.

This study has some limitations. First, we could not make a direct comparison of the eradication rate between 10d-CT and 10d-ST groups. Insufficient sample size for simultaneous comparison between the three groups made it impossible to directly compare 10d-CT and 10d-ST. Second, this study did not obtain any culture test result.

This trial provides evidence of the suboptimal efficacy of 7d-TT as the standard first-line treatment for *H. pylori* infection and that 10d-CT and 10d-ST were superior to 7d-TT in a country with clarithromycin resistance higher than 15%. The low eradication rates of the 7d-TT call for novel treatment options. In conclusion, novel therapies such as 10d-CT and 10d-ST can be recommended as alternative therapy for standard first-line treatment for *H. pylori* infection in Korea. Especially, 10d-CT may be the best new first-line alternative therapy for *H. pylori* infection in Korea. In addition, this study gives strong evidence of the adjustment of the Korean national guidelines for the treatment of *H. pylori*, which currently recommend TT as the first-line treatment for *H. pylori* infection. Furthermore, the results of this study could be used as a basis for changing Korea's National Health Insurance standards in *H. pylori* eradication.
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![Flow diagram of the study. A total of 1,141 patients participated in the study, of which 1,137 were included in the analyses.\
ITT, intention-to-treat; TT, triple therapy; ST, sequential therapy; CT, concomitant therapy; PP, per-protocol; UBT, urea breath test.](gnl-13-531f1){#f1-gnl-13-531}

![Eradication rates in the three treatment groups in the intent-to-treat (ITT) analysis. In the ITT analysis, the eradication rate in the 10 days (10d)-ST group was significantly higher than that in the 7d-TT group (76.3% vs 63.9%, p\<0.001). The eradication rate in the 10d-CT group was significantly higher than that in the 7d-TT group (81.2% vs 63.9%, p\<0.001).\
TT, triple therapy; ST, sequential therapy; CT, concomitant therapy.](gnl-13-531f2){#f2-gnl-13-531}

![Eradication rates in the three treatment groups in the per-protocol (PP) analysis. In the PP analysis, the eradication rate in the 10 days (10d)-ST group was significantly higher than that in the 7d-TT group (85.0% vs 71.4%, p\<0.001). The eradication rate in the 10d-CT group was significantly higher than that in the 7d-TT group (90.6% vs 71.4%, p\<0.001).\
TT, triple therapy; ST, sequential therapy; CT, concomitant therapy.](gnl-13-531f3){#f3-gnl-13-531}

###### 

Clinical Characteristics of the Enrolled Patients

  Characteristics                                                                 Total (n=1,137)   7d-TT (n=377)   10d-CT (n=383)   10d-ST (n=377)   p-value
  ------------------------------------------------------------------------------- ----------------- --------------- ---------------- ---------------- -------------------------------------------------
  Age, yr                                                                                                                                             0.51[\*](#tfn3-gnl-13-531){ref-type="table-fn"}
   Mean±SD                                                                        55.0±11.4         55.8±10.7       54.9±11.7        54.4±11.7        
   Median (range)                                                                 56 (22--84)       56 (27--79)     56 (23--80)      56 (22--84)      
  Sex                                                                                                                                                 0.87[†](#tfn4-gnl-13-531){ref-type="table-fn"}
   Male                                                                           621 (54.6)        208 (55.1)      205 (53.5)       208 (55.1)       
   Female                                                                         516 (45.3)        169 (44.8)      178 (46.4)       169 (44.8)       
  Smoking                                                                                                                                             0.70[†](#tfn4-gnl-13-531){ref-type="table-fn"}
   Never smoker                                                                   729 (64.1)        234 (62.0)      254 (66.3)       241 (63.9)       
   Ex-smoker                                                                      197 (17.3)        70 (18.5)       65 (16.9)        62 (16.4)        
   Current smoker                                                                 211 (18.5)        73 (19.3)       64 (16.7)        74 (19.6)        
  Alcohol consumption                                                                                                                                 0.61[†](#tfn4-gnl-13-531){ref-type="table-fn"}
   Never drinker                                                                  468 (41.1)        150 (39.7)      154 (40.2)       164 (43.5)       
   Ex-drinker                                                                     118 (10.3)        45 (11.9)       40 (10.4)        33 (8.7)         
   Current drinker                                                                551 (48.4)        182 (48.2)      189 (49.3)       180 (47.7)       
  General medical history[‡](#tfn5-gnl-13-531){ref-type="table-fn"}               498 (43.8)        172 (45.6)      160 (41.7)       166 (44.0)       0.56[†](#tfn4-gnl-13-531){ref-type="table-fn"}
  Past medical history of GI diseases[§](#tfn6-gnl-13-531){ref-type="table-fn"}   840 (73.8)        284 (75.3)      280 (73.1)       276 (73.2)       0.73[†](#tfn4-gnl-13-531){ref-type="table-fn"}
  Family history of gastric cancer                                                154 (13.5)        58 (15.3)       51 (13.3)        45 (11.9)        0.37[†](#tfn4-gnl-13-531){ref-type="table-fn"}
  Benign gastric ulcer                                                            183 (16.0)        67 (17.7)       56 (14.6)        60 (15.9)        0.49[†](#tfn4-gnl-13-531){ref-type="table-fn"}
  Benign duodenal ulcer                                                           132 (11.6)        39 (10.3)       43 (11.2)        50 (13.2)        0.43[†](#tfn4-gnl-13-531){ref-type="table-fn"}
  After ESD for EGC                                                               79 (6.9)          32 (8.4)        26 (6.7)         21 (5.5)         0.28[†](#tfn4-gnl-13-531){ref-type="table-fn"}
  MALT lymphoma                                                                   6 (0.5)           2 (0.5)         1 (0.2)          3 (0.3)          0.54[\*](#tfn3-gnl-13-531){ref-type="table-fn"}
  Atrophic or metaplastic gastritis                                               606 (53.3)        212 (56.2)      197 (51.4)       197 (52.2)       0.36[†](#tfn4-gnl-13-531){ref-type="table-fn"}
  Gastric adenoma                                                                 72 (6.3)          21 (5.5)        28 (7.3)         23 (6.1)         0.60[†](#tfn4-gnl-13-531){ref-type="table-fn"}
  Gastric polyp[II](#tfn7-gnl-13-531){ref-type="table-fn"}                        66 (5.8)          15 (3.9)        22 (5.7)         29 (7.6)         0.09[†](#tfn4-gnl-13-531){ref-type="table-fn"}
  Iron deficiency anemia                                                          2 (0.1)           1 (0.2)         1 (0.2)          \-               1.00[\*](#tfn3-gnl-13-531){ref-type="table-fn"}
  *Helicobacter pylori* (+) gastritis                                             381 (33.5)        116 (30.7)      128 (33.4)       137 (36.3)       0.26[†](#tfn4-gnl-13-531){ref-type="table-fn"}

Data are presented as number (%).

7d, 7 days; TT, triple therapy; CT, concomitant therapy; ST, sequential therapy; GI, gastrointestinal; ESD, endoscopic submucosal dissection; EGC, early gastric cancer; MALT, mucosa-associated lymphoid tissue.

Fisher exact test;

Chi-square test;

General medical history includes hypertension, arrhythmia, myocardial infarction, heart failure, diabetes mellitus, asthma, chronic obstructive pulmonary disease, liver cirrhosis, renal failure, and any cancer except GI cancer;

Past medical history of GI diseases includes esophagitis, gastric ulcer, duodenal ulcer, gastric cancer, past history of abdominal surgery, gastrectomy, intractable iron deficiency anemia, chronic idiopathic thrombocytopenic purpura, atrophic gastritis, and nonulcer dyspepsia;

Gastric polyp includes hyperplastic and inflammatory polyps.

###### 

Univariate and Multivariate Analyses of Factors Associated with Eradication Success (7d-TT vs 10d-CT)

  Characteristics                                                             Eradication   Univariate analysis   Multivariate analysis                                                      
  --------------------------------------------------------------------------- ------------- --------------------- ----------------------- ------------------- --------- -------------------- ---------
  Group                                                                                                                                                                                      
   TT                                                                         377 (100)     241 (63.9)            136 (36.1)              Reference                     Reference            
   CT                                                                         383 (100)     311 (81.2)            72 (18.8)               2.43 (1.75--3.39)   \<0.001   3.39 (2.33--4.94)    \<0.001
  Age, yr                                                                                                                                                                                    
   \<60                                                                       480           361 (75.2)            119 (24.8)              Reference                     Reference            
   ≥60                                                                        280           191 (68.2)            89 (31.8)               0.70 (0.51--0.98)   0.030     0.63 (0.44--0.90)    0.012
  Sex                                                                                                                                                                                        
   Male                                                                       413           319 (77.2)            94 (22.8)               Reference           0.002     Reference            
   Female                                                                     347           233 (67.1)            114 (32.9)              0.60 (0.43--0.83)             0.56 (0.39--0.80)    0.001
  Compliance                                                                                                                                                                                 
   \<80                                                                       116           48 (41.4)             68 (58.6)               Reference                     Reference            
   ≥80                                                                        644           504 (78.3)            140 (21.7)              5.10 (3.37--7.71)   \<0.001   7.22 (4.57--11.41)   \<0.001
  General medical history[\*](#tfn10-gnl-13-531){ref-type="table-fn"}                                                                                                   \-                   
   No                                                                         428           317 (74.1)            111 (25.9)              Reference                                          
   Yes                                                                        332           235 (70.8)            97 (29.2)               0.84 (0.61--1.16)   0.310                          
  Medical history of GI diseases[†](#tfn11-gnl-13-531){ref-type="table-fn"}                                                                                             \-                   
   No                                                                         196           138 (70.4)            58 (29.6)               Reference                                          
   Yes                                                                        564           414 (73.4)            150 (26.6)              1.16 (0.81--1.66)   0.410                          
  Family history of gastric cancer                                                                                                                                      \-                   
   No                                                                         651           471 (72.4)            180 (27.6)              Reference                                          
   Yes                                                                        109           81 (74.3)             28 (25.7)               1.10 (0.69--1.75)   0.670                          
  Concomitant medication                                                                                                                                                \-                   
   No                                                                         439           327 (74.5)            112 (25.5)              Reference                                          
   Yes                                                                        321           225 (70.1)            96 (29.9)               0.80 (0.58--1.10)   0.180                          

Data are presented as number or number (%).

7d, 7 days; TT, triple therapy; CT, concomitant therapy; OR, odds ratio; CI, confidence interval; GI, gastrointestinal.

General medical history includes hypertension, arrhythmia, myocardial infarction, heart failure, diabetes mellitus, asthma, chronic obstructive pulmonary disease, liver cirrhosis, renal failure, and any cancer except GI cancer;

Past medical history of GI diseases includes esophagitis, gastric ulcer, duodenal ulcer, gastric cancer, past history of abdominal surgery, gastrectomy, intractable iron deficiency anemia, chronic idiopathic thrombocytopenic purpura, atrophic gastritis, and nonulcer dyspepsia.

###### 

Univariate and Multivariate Analyses of Factors Associated with Eradication Success

  Characteristics                                                             Eradication   Univariate analysis   Multivariate analysis                                                     
  --------------------------------------------------------------------------- ------------- --------------------- ----------------------- ------------------- --------- ------------------- ---------
  Group                                                                                                                                                                                     
   TT                                                                         377           241 (63.9)            136 (36.1)              Reference                     Reference           
   ST                                                                         377           288 (76.4)            89 (23.6)               1.82 (1.32--2.50)   \<0.001   2.10 (1.50--2.95)   \<0.001
  Age, yr                                                                                                                                                                                   
   \<60                                                                       476           341 (71.6)            135 (28.4)              Reference                                         
   ≥60                                                                        278           188 (67.6)            90 (32.4)               0.82 (0.60--1.14)   0.246                         
  Sex                                                                                                                                                                                       
   Male                                                                       416           316 (75.9)            100 (24.1)              Reference                     Reference           
   Female                                                                     338           213 (63.0)            125 (37.0)              0.53 (0.39--0.73)   \<0.001   0.57 (0.41--0.80)   0.001
  Compliance                                                                                                                                                                                
   \<80                                                                       106           43 (40.6)             63 (59.4)               Reference                     Reference           
   ≥80                                                                        648           486 (75)              162 (25)                4.39 (2.86--6.73)   \<0.001   4.79 (3.07--7.47)   \<0.001
  General medical history[\*](#tfn14-gnl-13-531){ref-type="table-fn"}                                                                                                                       
   No                                                                         415           292 (70.4)            123 (29.6)              Reference                                         
   Yes                                                                        339           237 (70.0)            102 (30.0)              0.97 (0.71--1.33)   0.890                         
  Medical history of GI diseases[†](#tfn15-gnl-13-531){ref-type="table-fn"}                                                                                                                 
   No                                                                         195           138 (70.7)            57 (29.2)               Reference                                         
   Yes                                                                        559           391 (70.0)            168 (30.0)              0.96 (0.67--1.37)   0.830                         
  Family history of gastric cancer                                                                                                                                                          
   No                                                                         651           456 (70.0)            195 (30.0)              Reference                                         
   Yes                                                                        103           73 (70.9)             30 (29.1)               1.04 (0.65--1.64)   0.860                         
  Concomitant medication                                                                                                                                                                    
   No                                                                         420           303 (72.1)            117 (27.9)              Reference                                         
   Yes                                                                        334           226 (67.7)            108 (32.3)              0.80 (0.59--1.10)   0.180                         

Data are presented as number or number (%).

OR, odds ratio; CI, confidence interval; TT, triple therapy; ST, sequential therapy; GI, gastrointestinal.

General medical history includes hypertension, arrhythmia, myocardial infarction, heart failure, diabetes mellitus, asthma, chronic obstructive pulmonary disease, liver cirrhosis, renal failure, and any cancer except GI cancer;

Past medical history of GI diseases includes esophagitis, gastric ulcer, duodenal ulcer, gastric cancer, past history of abdominal surgery, gastrectomy, intractable iron deficiency anemia, chronic idiopathic thrombocytopenic purpura, atrophic gastritis, and nonulcer dyspepsia.

###### 

Adverse Events According to Regimen

  Adverse events                    Total (n=602)   7d-TT (n=166)   10d-CT (n=243)   10d-ST (n=193)
  --------------------------------- --------------- --------------- ---------------- ----------------
  Diarrhea                          121             42              51               28
  Dysgeusia                         91              36              34               21
  Nausea                            56              11              19               26
  Non-cardiac chest pain            53              11              23               19
  Dyspepsia                         44              12              13               19
  Allergic reaction                 29              11              11               7
  Headache                          28              4               14               10
  Gastroesophageal reflux disease   24              7               10               7
  Dizziness                         18              3               9                6
  Fatigue                           17              2               9                6
  Abdominal pain                    15              3               6                6
  Others                            106             24              44               38

TT, standard triple therapy; CT, concomitant therapy; ST, sequential therapy.

[^1]: Beom Jin Kim and Hyuk Lee contributed equally to this work as first authors.
